spacer
home > ict > autumn 2016 > does size really matter?
PUBLICATIONS
International Clinical Trials

Does Size Really Matter?

Over the past few years, outsourcing clinical trials has become an attractive option for sponsored pharmaceutical research. Therapeutic expertise, resource management, technological advantages and cost cutting are some of the primary reasons for any biopharmaceutical sponsor to outsource clinical trials. This has led to tremendous growth in the size and number of CROs in the past two decades. Most of them position themselves as a fullservice CRO in the drug development market, although – based on study-specific requirements – the majority of them are ready to sub-source for their functional needs.

Collaborating with a CRO is now an essential and significant step for sponsors during the clinical development process. The dynamic shift in outsourcing methodology and service fragmentation has left them with critical decisions to be taken at the juncture of CRO sourcing. There are variable sizes of companies on both the sponsor and the CRO side, and the principle of ‘one size fits all’ is not pragmatic from an operability perspective.

Different Options


Full-service and functional outsourcing remain as two distinct but basic models of collaboration. Traditionally, per-study outsourcing has been followed until recently, when strategic partnerships between Big Pharma and sizeable CROs began gaining popularity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mohamed El Malt, MD, PhD, is Chief Medical Consultant at Europital. In addition to 15 years of working as a general and oncology surgeon, Mohamed has more than 32 years of experience as a medical doctor, 18 of which he spent in clinical research and drug development at academic medical centres, as well as in pharma companies and CROs as an investigator, project leader and medical director.
spacer
Mohamed El Malt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Nanoparticle Tracking Analysis. A Review of Applications and Usage in the Analysis of Exosomes and Microvesicles

NanoSight

The study of exosomes and other cell-derived microvesicles is an area of rapidly growing importance and the subject of intense interest and research. The previous lack of suitable methods for their detection, analysis, enumeration and phenotyping is proving to be a significant limitation in these studies. This mini-review shows the degree to which the technique of Nanoparticle Tracking Analysis (NTA) is helping to address these problems.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement